10 hasil untuk "Lawrence Corey"
Menampilkan 1–10 · 0,89 detik · RSS
-
Artikel Jurnal
SARS-CoV-2 Variants in Patients with Immunosuppression
SARS-CoV-2 and Immunosuppression In this article, the authors discuss the challenges of SARS-CoV-2 infection in patients with a weakened immune system, including the potential implications regardin...
-
Artikel Jurnal Teks lengkap
After the pandemic: perspectives on the future trajectory of COVID-19
-
Artikel Jurnal
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
BACKGROUND: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. METHODS: viral particles) or placebo. The primary end…
-
Artikel Jurnal Teks lengkap
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
BACKGROUND: The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS: viral particles) or placebo. The primary end points were vaccine efficacy against moderate to…
-
Artikel Jurnal
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe…
-
Artikel Jurnal
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
BACKGROUND: NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b-3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North…
-
Artikel Jurnal Teks lengkap
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label…
-
Artikel Jurnal
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind…
-
Artikel Jurnal Teks lengkap
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: ) of acquired isolates was measured with the TZM-bl assay. RESULTS:
-
Artikel Jurnal
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later…